| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6274037 | Neuroscience | 2014 | 11 Pages |
Abstract
The complex, multifactorial pathomechanism of SNHLs most likely requires drugs acting on multiple targets for effective therapy. Rasagiline, with its multi-target action and favorable adverse effects profile, might be a good candidate for a clinical trial testing the otoprotective indication.
Keywords
Lateral olivocochlear efferentslateral olivocochlearHEPESVGSCVGCCRNSIHCsABRMAO2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acidROSHearing lossfractional releaseanalysis of varianceANOVADopamineRasagilineinner hair cellsLocmonoamine oxidase inhibitorElectron microscopyauditory brainstem responsevoltage-gated sodium channelvoltage-gated calcium channelKanamycinsensorineural hearing lossGluglutamatereactive nitrogen speciesReactive oxygen species
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
G. Polony, V. Humli, R. Andó, M. Aller, T. Horváth, A. Harnos, L. Tamás, E.S. Vizi, T. Zelles,